Who Owns Michelob Ultra? Owned by Anheuser-Busch InBev, Michelob Ultra is a multinational beverage and brewing company based in Leuven, Belgium. Anheuser-Busch InBev is the largest brewing company ...

Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan Healthcare Conference with a deal to buy Scorpion Therapeutics ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in upfront and near-term payments for global rights to an asset that is ...

Eli Lilly spooked the market with warnings of a small revenue slowdown in Q4 2024. Lilly nevertheless delivered good news about its prospects for sales growth in 2025. The company also dropped a ...

SAN FRANCISCO — Eli Lilly said Monday it would acquire a cancer program from startup Scorpion Therapeutics in a deal worth up to $2.5 billion, as the Indianapolis company broadens its pipeline.

Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

Ricks, Lilly chair and CEO. "The rest of our medicines performed within our expectations." "2024 was a pivotal and highly successful year for Lilly, and we expect to continue our momentum in 2025 ...

In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year Among those who achieved clinical ...

Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Eli Lilly shares could remain under the microscope on Wednesday after falling sharply ...

Global pharma major Eli Lilly and Company is setting up a new global capability centre in Hyderabad, a facility for which more than 1,000 people are to be recruited. The Lilly Capability Centre ...

Eli Lilly & Co.’s fourth-quarter revenue fell short of analysts’ estimates as the drugmaker struggled to forecast demand for its popular weight-loss and diabetes shots for the second quarter ...